Home Testing Paves Way for eCommerce Expansion Post Coronavirus Outbreak

The coronavirus outbreak has subsided significantly, as the end of 2021 is nearing. This outbreak led to several developments in the healthcare industry, especially in the vaginal panel testing market in EMEA. The trend of home testing has benefitted healthcare companies within the market landscape. This is why manufacturers are tapping revenue opportunities through eCommerce to expand their revenue streams.

Since manufacturers witnessed supply shortage for laboratory items during the peak pandemic period, companies in the vaginal panel testing market in EMEA are increasing efforts to maintain optimum inventory levels. Surge in spending capacity of individuals and relaxation of COVID-19 restrictions across countries is contributing toward the increase in overall revenue flow in the market.

emea vaginal panel testing market infographic

Request a sample to get extensive insights into the Vaginal Panel Testing Market

Next-gen Assays Help Fewer Recurrent Doctor Office Visits

Companies are increasing the production of molecular nucleic acid amplification tests (NAAT) to support the detection of vaginitis and vaginosis. The high prevalence of candida vaginitis, trichomoniasis, and bacterial vaginosis (BV) among women has led to innovations in assays. Manufacturers are increasing the availability of vaginitis panels that aid in the detection of yeast infections and trichomoniasis.

The vaginal panel testing market in EMEA is projected to cross US$ 175 Mn by 2031. Companies are increasing R&D in assays that enable better guided drug treatment, reduced suffering in affected women, and fewer recurrent doctor’s office visits. Such assays are helping healthcare companies to advance in molecular testing.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Innovations in Panels Help in Detection of Sexual and Vaginal Disease States

The vaginal panel testing market in EMEA is slated to clock a CAGR of 3.9% during the forecast period. Nevertheless, intensified competition in the market is challenging companies to develop an assay portfolio that caters to both sexual and vaginal health, which includes vaginitis testing alongside comprehensive sexually transmitted infections (STIs) and viral load testing.

There is a growing demand for vaginal panels that provide the flexibility to detect several infections and disease states with only one vaginal swab, which includes gonorrhea and candida species. Since the CDC (Centers for Disease Control and Prevention) is recommending the testing of trichomonas vaginalis (TV) in all women seeking treatment for vaginal discharge, such findings are leading to product sales.

At-home Vaginal Panel Testing Products Provide Privacy and Convenience to Women

Privacy and convenience are becoming important factors in the vaginal panel testing market in EMEA. This has led to innovations in affordable at-home testing products. Manufacturers in the vaginal panel testing market in EMEA are boosting the production of lab certified vaginal panels that help to generate results in less than five days. Since many women are concerned for unusual changes in the color, odor, and texture of vaginal discharge, at-home vaginal panel testing products are providing them several advantages.

At-home vaginal panel testing products eliminate the need of awkward conversations with peers and physicians, and help to screen common causes of abnormal vaginal discharge at comfort of the home.

FDA-authorized Products Enable Companies to Gain Competitive Edge

Molecular testing using a DNA probe for the detection of candida species and gardnerella vaginalis is growing prominent in the vaginal panel testing market in EMEA. Companies are increasing research in this space, since vaginitis accounts for several doctor office visits each year. Since the complications of BV can be significant in pregnant women, manufacturers are boosting output capacities in vaginal panel testing products.

In order to boost credibility, companies in the vaginal panel testing market in EMEA are increasing the availability of FDA-authorized products. These include polymerase chain reaction (PCR) assay and microbiome-based vaginal panel tests. Companies are innovating in assays that support antimicrobial resistance initiatives in women by detecting the presence of Candida krusei and C. glabrata.

emea vaginal panel testing market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on Vaginal Panel Testing Market

Analysts’ Viewpoint

Affordable at-home testing trends are creating revenue opportunities for companies in the vaginal panel testing market in EMEA in eCommerce during the post coronavirus period. Since traditional diagnostic techniques tend to be subjective with variable sensitivity and specificity, healthcare companies are capitalizing on this opportunity to innovate in vaginal panels. However, a negative test result done with vaginitis panel testing by DNA direct probe does not rule out the presence of microorganisms below the test sensitivity. Hence, companies should increase awareness about using vaginitis panel testing by DNA direct probe with vaginal specimens to improve medical outcomes. There is a growing demand for products that reduce repeated doctor visits and improve antimicrobial stewardship.

Europe and Middle East & Africa Vaginal Panel Testing Market: Overview

  • Vaginal panel testing is an automated qualitative in vitro diagnostic test for the direct detection of DNA targets from bacteria associated with bacterial vaginosis, candida species associated with vulvovaginal candidiasis, and trichomonas vaginalis
  • The test utilizes real-time polymerase chain reaction (PCR) for the amplification of specific DNA targets and utilizes fluorogenic target-specific hybridization probes to detect and differentiate DNA from
  • Vaginal panel assists in the diagnosis of vaginal infections in women with a clinical presentation consistent with bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis

Europe and Middle East & Africa Vaginal Panel Testing Market: Key Drivers

  • Accurate screening & detection of bacterial, yeast, fungi, and viral samples in clinical pathology using vaginal testing panels has allowed less turnaround time due to lower chances of producing false positive results because of their broad coverage of microbes of different classes, sensitivity, and effectiveness for the production of the results. This will help in more women undergoing diagnostic tests for vaginal testing, which, in turn, is likely to increase the number of diagnostic vaginal testing procedures.
  • Moreover, incidence of vaginal disorders is common among young women, and around 32% of the female population struggles with different kinds of vaginal complications. Most vaginal infections are asymptomatic and hence, it is difficult to predict the initial onset. Therefore, more women are likely to undergo molecular diagnostic tests for vaginal infections, which is projected drive the global vaginal testing panels market.

Market Segmentation: Europe and Middle East & Africa Vaginal Panel Testing Market

  • In terms of type, the vaginal panel testing market in EMEA has been bifurcated into direct molecular DNA probe and molecular nucleic acid amplification test (NAAT)
  • Based on application, the vaginal panel testing market in EMEA has been classified into bacterial vaginosis, vulvovaginal candidiasis, chlamydia, gonorrhoea, trichomoniasis, and others
  • In terms of end-user, the vaginal panel testing market in EMEA has been divided into hospitals, diagnostic laboratories, and others
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The vaginal panel testing market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031, along with market size estimations.

Regional Overview: Europe and Middle East & Africa Vaginal Panel Testing Market

  • Europe dominated the vaginal panel testing market in EMEA in 2020, accounting for 87.9% share. Increase in health awareness, rise in expenditure on healthcare infrastructure, and surge in demand for better healthcare facilities fuel the growth of the vaginal testing panels market in Europe.
  • Germany is projected to be an attractive market from 2021 to 2031. The country is anticipated to account for significant share of the market in Europe during the forecast period. Growth of the market in the country can be attributed to increase in research activities, rise in government funding for research & development, and surge in the number of biotechnology companies.

Major Players

  • The vaginal panel testing market report concludes with the company profiles section, which includes key information about major players in the vaginal panel testing market in EMEA
  • Leading players analyzed in the report include
    • Abbott Laboratories
    • Atrida
    • Becton
    • Dickenson and Company
    • Cepheid (Danaher Corporation)
    • F. Hoffmann-La Roche Ltd.
    • Hologic, Inc.
    • Laboratory Corporation of America Holdings
    • Mologic Ltd.
    • QIAGEN
    • Quest Diagnostics Incorporated
    • Quidel Corporation
  • Each of these players has been profiled in the vaginal panel testing market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments

Europe and Middle East & Africa Vaginal Panel Testing Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 117.5 Mn

Market Forecast Value in 2031

US$ 175 Mn

Growth Rate (CAGR)

3.9%

Forecast Period

2021–2031

Historical Data Available for

2017–2019

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis at as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Type
    • Direct Molecular DNA Probe
    • Molecular Nucleic Acid Amplification Test (NAAT)
  • Application
    • Bacterial Vaginosis
    • Vulvovaginal Candidiasis
    • Chlamydia
    • Gonorrhoea
    • Trichomoniasis
    • Others
  • End-user
    • Hospitals
    • Diagnostic Centers
    • Others

Regions Covered

  • Europe
  • Middle East & Africa

Countries Covered

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Finland
  • Austria
  • Switzerland
  • Benelux
  • Norway
  • Poland
  • Rest of Europe

Companies Profiled

  • Abbott Laboratories
  • Atrida
  • Becton, Dickenson and Company
  • Cepheid (Danaher Corporation)
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Laboratory Corporation of America Holdings
  • Mologic Ltd.
  • QIAGEN
  • Quest Diagnostics Incorporated
  • Quidel Corporation
  • Other prominent players

Customization Scope

Available upon request

Pricing

Available upon request

Europe and Middle East & Africa Vaginal Panel Testing Market – Scope of Report

TMR’s report on the vaginal panel testing market in EMEA studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides revenue of the vaginal panel testing market in EMEA for the period 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the vaginal panel testing market in EMEA from 2021 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the vaginal panel testing market in EMEA.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the vaginal panel testing market in EMEA.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the vaginal panel testing market in EMEA. These serve as valuable tools for existing market players as well as for entities interested in participating in the vaginal panel testing market in EMEA.

The report delves into the competition landscape of the vaginal panel testing market in EMEA. Key players operating in the vaginal panel testing market in EMEA have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the vaginal panel testing market in EMEA profiled in this report.

Key Questions Answered in Europe and Middle East & Africa Vaginal Panel Testing Market Report

  • What is the sales/revenue generated by vaginal panel testing across all regions during the forecast period?
  • What are the opportunities in the vaginal panel testing market in EMEA?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is likely to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Europe and Middle East & Africa Vaginal Panel Testing Market – Research Objectives and Research Approach

The comprehensive report on the vaginal panel testing market in EMEA begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments are visually appealing to readers. This allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the vaginal panel testing market in EMEA in terms of type, application, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the vaginal panel testing market in EMEA.

Europe and Middle East & Africa Vaginal Panel Testing Market – Segmentation

TMR’s study on the vaginal panel testing market in EMEA includes information divided into four segments: type, application, end-user, and region. Changing industry trends and other market dynamics associated with these segments of the vaginal panel testing market in EMEA are discussed in detail.

Type
  • Direct Molecular DNA Probe
  • Molecular Nucleic Acid Amplification Test (NAAT)
Application
  • Bacterial Vaginosis
  • Vulvovaginal Candidiasis
  • Chlamydia
  • Gonorrhoea
  • Trichomoniasis
  • Others
End-user
  • Hospitals
  • Diagnostic Centers
  • Others
Region
  • Europe
  • Middle East & Africa

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Europe and Middle East & Africa Vaginal Panel Testing Market

4. Market Overview

    4.1. Introduction

        4.1.1. Market Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Europe and Middle East & Africa Vaginal Panel Testing Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. Key Industry Events (mergers, acquisitions, partnerships, etc.)

    5.2. Technological Advancements

    5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long-term impact)

6. Europe and Middle East & Africa Vaginal Panel Testing Market Analysis and Forecast, by Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Type, 2018–2030

        6.3.1. Direct Molecular DNA Probe

        6.3.2. Molecular Nucleic Acid Amplification Test (NAAT)

    6.4. Market Attractiveness Analysis, by Type

7. Europe and Middle East & Africa Vaginal Panel Testing Market Analysis and Forecast, by Application

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Application, 2018–2030

        7.3.1. Bacterial Vaginosis

        7.3.2. Vulvovaginal Candidiasis

        7.3.3. Chlamydia

        7.3.4. Gonorrhoea

        7.3.5. Trichomoniasis

        7.3.6. Others

    7.4. Market Attractiveness Analysis, by Application

8. Europe and Middle East & Africa Vaginal Panel Testing Market Analysis and Forecast, by End-user

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by End-user, 2018–2030

        8.3.1. Hospitals

        8.3.2. Diagnostic Centers

        8.3.3. Others

    8.4. Market Attractiveness Analysis, by End-user

9. Europe and Middle East & Africa Vaginal Panel Testing Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. Europe

        9.2.2. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. Europe Vaginal Panel Testing Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Type, 2018–2030

        10.2.1. Direct molecular Direct Molecular DNA Probe

        10.2.2. Molecular Nucleic Acid Amplification Test (NAAT)

    10.3. Market Value Forecast, by Application, 2018–2030

        10.3.1. Bacterial Vaginosis

        10.3.2. Vulvovaginal Candidiasis

        10.3.3. Chlamydia

        10.3.4. Gonorrhoea

        10.3.5. Trichomoniasis

        10.3.6. Others

    10.4. Market Value Forecast, by End-user, 2018–2030

        10.4.1. Hospitals

        10.4.2. Diagnostic Centers

        10.4.3. Others

    10.5. Market Value Forecast, by Country, 2018–2030

        10.5.1. Germany

            10.5.1.1. Market Value Forecast, by Type, 2017–2031

                10.5.1.1.1. Polymerase Chain Reaction (PCR) Assay

                10.5.1.1.2. Direct Molecular DNA Probe

                10.5.1.1.3. Molecular Nucleic Acid Amplification Test (NAAT)

            10.5.1.2. Market Value Forecast, by Application, 2017–2031

                10.5.1.2.1. Bacterial Vaginosis

                10.5.1.2.2. Vulvovaginal Candidiasis

                10.5.1.2.3. Chlamydia

                10.5.1.2.4. Gonorrhoea

                10.5.1.2.5. Trichomoniasis

                10.5.1.2.6. Others

            10.5.1.3. Market Value Forecast, by End-user, 2017–2031

                10.5.1.3.1. Hospital

                10.5.1.3.2. Diagnostic Centers

                10.5.1.3.3. Others

        10.5.2. U.K.

            10.5.2.1. Market Value Forecast, by Type, 2017–2031

                10.5.2.1.1. Polymerase Chain Reaction (PCR) Assay

                10.5.2.1.2. Direct Molecular DNA Probe

                10.5.2.1.3. Molecular Nucleic Acid Amplification Test (NAAT)

            10.5.2.2. Market Value Forecast, by Application, 2017–2031

                10.5.2.2.1. Bacterial Vaginosis

                10.5.2.2.2. Vulvovaginal Candidiasis

                10.5.2.2.3. Chlamydia

                10.5.2.2.4. Gonorrhoea

                10.5.2.2.5. Trichomoniasis

                10.5.2.2.6. Others

            10.5.2.3. Market Value Forecast, by End-user, 2017–2031

                10.5.2.3.1. Hospital

                10.5.2.3.2. Diagnostic Centers

                10.5.2.3.3. Others

        10.5.3. France

            10.5.3.1. Market Value Forecast, by Type, 2017–2031

                10.5.3.1.1. Direct Molecular DNA Probe

                10.5.3.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

            10.5.3.2. Market Value Forecast, by Application, 2017–2031

                10.5.3.2.1. Bacterial Vaginosis

                10.5.3.2.2. Vulvovaginal Candidiasis

                10.5.3.2.3. Chlamydia

                10.5.3.2.4. Gonorrhoea

                10.5.3.2.5. Trichomoniasis

                10.5.3.2.6. Others

            10.5.3.3. Market Value Forecast, by End-user, 2017–2031

                10.5.3.3.1. Hospital

                10.5.3.3.2. Diagnostic Centers

                10.5.3.3.3. Others

        10.5.4. Italy

            10.5.4.1. Market Value Forecast, by Type, 2017–2031

                10.5.4.1.1. Direct Molecular DNA Probe

                10.5.4.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

            10.5.4.2. Market Value Forecast, by Application, 2017–2031

                10.5.4.2.1. Bacterial Vaginosis

                10.5.4.2.2. Vulvovaginal Candidiasis

                10.5.4.2.3. Chlamydia

                10.5.4.2.4. Gonorrhoea

                10.5.4.2.5. Trichomoniasis

                10.5.4.2.6. Others

            10.5.4.3. Market Value Forecast, by End-user, 2017–2031

                10.5.4.3.1. Hospital

                10.5.4.3.2. Diagnostic Centers

                10.5.4.3.3. Others

        10.5.5. Spain

            10.5.5.1. Market Value Forecast, by Type, 2017–2031

                10.5.5.1.1. Direct Molecular DNA Probe

                10.5.5.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

            10.5.5.2. Market Value Forecast, by Application, 2017–2031

                10.5.5.2.1. Bacterial Vaginosis

                10.5.5.2.2. Vulvovaginal Candidiasis

                10.5.5.2.3. Chlamydia

                10.5.5.2.4. Gonorrhoea

                10.5.5.2.5. Trichomoniasis

                10.5.5.2.6. Others

            10.5.5.3. Market Value Forecast, by End-user, 2017–2031

                10.5.5.3.1. Hospital

                10.5.5.3.2. Diagnostic Centers

                10.5.5.3.3. Others

        10.5.6. Sweden

            10.5.6.1. Market Value Forecast, by Type, 2017–2031

                10.5.6.1.1. Direct Molecular DNA Probe

                10.5.6.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

            10.5.6.2. Market Value Forecast, by Application, 2017–2031

                10.5.6.2.1. Bacterial Vaginosis

                10.5.6.2.2. Vulvovaginal Candidiasis

                10.5.6.2.3. Chlamydia

                10.5.6.2.4. Gonorrhoea

                10.5.6.2.5. Trichomoniasis

                10.5.6.2.6. Others

            10.5.6.3. Market Value Forecast, by End-user, 2017–2031

                10.5.6.3.1. Hospital

                10.5.6.3.2. Diagnostic Centers

                10.5.6.3.3. Others

        10.5.7. Denmark

            10.5.7.1. Market Value Forecast, by Type, 2017–2031

                10.5.7.1.1. Direct Molecular DNA Probe

                10.5.7.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

            10.5.7.2. Market Value Forecast, by Application, 2017–2031

                10.5.7.2.1. Bacterial Vaginosis

                10.5.7.2.2. Vulvovaginal Candidiasis

                10.5.7.2.3. Chlamydia

                10.5.7.2.4. Gonorrhoea

                10.5.7.2.5. Trichomoniasis

                10.5.7.2.6. Others

            10.5.7.3. Market Value Forecast, by End-user, 2017–2031

                10.5.7.3.1. Hospital

                10.5.7.3.2. Diagnostic Centers

                10.5.7.3.3. Others

        10.5.8. Finland

            10.5.8.1. Market Value Forecast, by Type, 2017–2031

                10.5.8.1.1. Direct Molecular DNA Probe

                10.5.8.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

            10.5.8.2. Market Value Forecast, by Application, 2017–2031

                10.5.8.2.1. Bacterial Vaginosis

                10.5.8.2.2. Vulvovaginal Candidiasis

                10.5.8.2.3. Chlamydia

                10.5.8.2.4. Gonorrhoea

                10.5.8.2.5. Trichomoniasis

                10.5.8.2.6. Others

            10.5.8.3. Market Value Forecast, by End-user, 2017–2031

                10.5.8.3.1. Hospital

                10.5.8.3.2. Diagnostic Centers

                10.5.8.3.3. Others

        10.5.9. Austria

            10.5.9.1. Market Value Forecast, by Type, 2017–2031

                10.5.9.1.1. Direct Molecular DNA Probe

                10.5.9.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

            10.5.9.2. Market Value Forecast, by Application, 2017–2031

                10.5.9.2.1. Bacterial Vaginosis

                10.5.9.2.2. Vulvovaginal Candidiasis

                10.5.9.2.3. Chlamydia

                10.5.9.2.4. Gonorrhoea

                10.5.9.2.5. Trichomoniasis

                10.5.9.2.6. Others

            10.5.9.3. Market Value Forecast, by End-user, 2017–2031

                10.5.9.3.1. Hospital

                10.5.9.3.2. Diagnostic Centers

                10.5.9.3.3. Others

        10.5.10. Switzerland

            10.5.10.1. Market Value Forecast, by Type, 2017–2031

                10.5.10.1.1. Direct Molecular DNA Probe

                10.5.10.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

            10.5.10.2. Market Value Forecast, by Application, 2017–2031

                10.5.10.2.1. Bacterial Vaginosis

                10.5.10.2.2. Vulvovaginal Candidiasis

                10.5.10.2.3. Chlamydia

                10.5.10.2.4. Gonorrhoea

                10.5.10.2.5. Trichomoniasis

                10.5.10.2.6. Others

            10.5.10.3. Market Value Forecast, by End-user, 2017–2031

                10.5.10.3.1. Hospital

                10.5.10.3.2. Diagnostic Centers

                10.5.10.3.3. Others

        10.5.11. Benelux

            10.5.11.1. Market Value Forecast, by Type, 2017–2031

                10.5.11.1.1. Direct Molecular DNA Probe

                10.5.11.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

            10.5.11.2. Market Value Forecast, by Application, 2017–2031

                10.5.11.2.1. Bacterial Vaginosis

                10.5.11.2.2. Vulvovaginal Candidiasis

                10.5.11.2.3. Chlamydia

                10.5.11.2.4. Gonorrhoea

                10.5.11.2.5. Trichomoniasis

                10.5.11.2.6. Others

            10.5.11.3. Market Value Forecast, by End-user, 2017–2031

                10.5.11.3.1. Hospital

                10.5.11.3.2. Diagnostic Centers

                10.5.11.3.3. Others

        10.5.12. Norway

            10.5.12.1. Market Value Forecast, by Type, 2017–2031

                10.5.12.1.1. Direct Molecular DNA Probe

                10.5.12.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

            10.5.12.2. Market Value Forecast, by Application, 2017–2031

                10.5.12.2.1. Bacterial Vaginosis

                10.5.12.2.2. Vulvovaginal Candidiasis

                10.5.12.2.3. Chlamydia

                10.5.12.2.4. Gonorrhoea

                10.5.12.2.5. Trichomoniasis

                10.5.12.2.6. Others

            10.5.12.3. Market Value Forecast, by End-user, 2017–2031

                10.5.12.3.1. Hospital

                10.5.12.3.2. Diagnostic Centers

                10.5.12.3.3. Others

        10.5.13. Poland

            10.5.13.1. Market Value Forecast, by Type, 2017–2031

                10.5.13.1.1. Direct Molecular DNA Probe

                10.5.13.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

            10.5.13.2. Market Value Forecast, by Application, 2017–2031

                10.5.13.2.1. Bacterial Vaginosis

                10.5.13.2.2. Vulvovaginal Candidiasis

                10.5.13.2.3. Chlamydia

                10.5.13.2.4. Gonorrhoea

                10.5.13.2.5. Trichomoniasis

                10.5.13.2.6. Others

            10.5.13.3. Market Value Forecast, by End-user, 2017–2031

                10.5.13.3.1. Hospital

                10.5.13.3.2. Diagnostic Centers

                10.5.13.3.3. Others

        10.5.14. Rest of Europe

            10.5.14.1. Market Value Forecast, by Type, 2017–2031

                10.5.14.1.1. Direct Molecular DNA Probe

                10.5.14.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

            10.5.14.2. Market Value Forecast, by Application, 2017–2031

                10.5.14.2.1. Bacterial Vaginosis

                10.5.14.2.2. Vulvovaginal Candidiasis

                10.5.14.2.3. Chlamydia

                10.5.14.2.4. Gonorrhoea

                10.5.14.2.5. Trichomoniasis

                10.5.14.2.6. Others

            10.5.14.3. Market Value Forecast, by End-user, 2017–2031

                10.5.14.3.1. Hospital

                10.5.14.3.2. Diagnostic Centers

                10.5.14.3.3. Others

    10.6. Market Attractiveness Analysis

        10.6.1. By Type

        10.6.2. By Application

        10.6.3. By End-user

        10.6.4. By Country

11. Middle East & Africa Vaginal Testing Panels Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Type, 2017–2031

        11.2.1. Direct Molecular DNA Probe

        11.2.2. Molecular Nucleic Acid Amplification Test (NAAT)

    11.3. Market Value Forecast, by Application, 2017–2031

        11.3.1. Bacterial Vaginosis

        11.3.2. Vulvovaginal Candidiasis

        11.3.3. Chlamydia

        11.3.4. Gonorrhoea

        11.3.5. Trichomoniasis

        11.3.6. Others

    11.4. Market Value Forecast, by End-user, 2017–2031

        11.4.1. Hospital

        11.4.2. Diagnostic Centers

        11.4.3. Others

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. GCC Countries

            11.5.1.1. Market Value Forecast, by Type, 2017–2031

                11.5.1.1.1. Direct Molecular DNA Probe

                11.5.1.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

            11.5.1.2. Market Value Forecast, by Application, 2017–2031

                11.5.1.2.1. Bacterial Vaginosis

                11.5.1.2.2. Vulvovaginal Candidiasis

                11.5.1.2.3. Chlamydia

                11.5.1.2.4. Gonorrhoea

                11.5.1.2.5. Trichomoniasis

                11.5.1.2.6. Others

            11.5.1.3. Market Value Forecast, by End-user, 2017–2031

                11.5.1.3.1. Hospital

                11.5.1.3.2. Diagnostic Centers

                11.5.1.3.3. Others

        11.5.2. South Africa

            11.5.2.1. Market Value Forecast, by Type, 2017–2031

                11.5.2.1.1. Direct Molecular DNA Probe

                11.5.2.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

            11.5.2.2. Market Value Forecast, by Application, 2017–2031

                11.5.2.2.1. Bacterial Vaginosis

                11.5.2.2.2. Vulvovaginal Candidiasis

                11.5.2.2.3. Chlamydia

                11.5.2.2.4. Gonorrhoea

                11.5.2.2.5. Trichomoniasis

                11.5.2.2.6. Others

            11.5.2.3. Market Value Forecast, by End-user, 2017–2031

                11.5.2.3.1. Hospital

                11.5.2.3.2. Diagnostic Centers

                11.5.2.3.3. Others

        11.5.3. Rest of Middle East & Africa

            11.5.3.1. Market Value Forecast, by Type, 2017–2031

                11.5.3.1.1. Direct Molecular DNA Probe

                11.5.3.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

            11.5.3.2. Market Value Forecast, By Application, 2017–2031

                11.5.3.2.1. Bacterial Vaginosis

                11.5.3.2.2. Vulvovaginal Candidiasis

                11.5.3.2.3. Chlamydia

                11.5.3.2.4. Gonorrhoea

                11.5.3.2.5. Trichomoniasis

                11.5.3.2.6. Others

            11.5.3.3. Market Value Forecast, by End-user, 2017–2031

                11.5.3.3.1. Hospital

                11.5.3.3.2. Diagnostic Centers

                11.5.3.3.3. Others

    11.6. Market Attractiveness Analysis

        11.6.1. By Type

        11.6.2. By Application

        11.6.3. By End-user

        11.6.4. By Country

12. Competition Landscape

    12.1. Market Player - Competition Matrix (by tier and size of companies)

    12.2. Company Profiles

        12.2.1. Becton Dickenson

            12.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.1.2. Product Portfolio

            12.2.1.3. SWOT Analysis

            12.2.1.4. Strategic Overview

        12.2.2. Atrida

            12.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.2.2. Product Portfolio

            12.2.2.3. SWOT Analysis

            12.2.2.4. Strategic Overview

        12.2.3. Hologic, Inc.

            12.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.3.2. Product Portfolio

            12.2.3.3. SWOT Analysis

            12.2.3.4. Strategic Overview

        12.2.4. Quest Diagnostics Incorporated

            12.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.4.2. Product Portfolio

            12.2.4.3. SWOT Analysis

            12.2.4.4. Strategic Overview

        12.2.5. Quidel Corporation

            12.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.5.2. Product Portfolio

            12.2.5.3. SWOT Analysis

            12.2.5.4. Strategic Overview

        12.2.6. Mologic Ltd.

            12.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.6.2. Product Portfolio

            12.2.6.3. SWOT Analysis

            12.2.6.4. Strategic Overview

        12.2.7. F. Hoffmann-La Roche Ltd.

            12.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.7.2. Product Portfolio

            12.2.7.3. SWOT Analysis

            12.2.7.4. Strategic Overview

        12.2.8. QIAGEN

            12.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.8.2. Product Portfolio

            12.2.8.3. SWOT Analysis

            12.2.8.4. Strategic Overview

        12.2.9. Abbott Laboratories

            12.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.9.2. Product Portfolio

            12.2.9.3. SWOT Analysis

            12.2.9.4. Strategic Overview

        12.2.10. Cepheid (Danaher Corporation)

            12.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.10.2. Product Portfolio

            12.2.10.3. SWOT Analysis

            12.2.10.4. Strategic Overview

        12.2.11. Laboratory Corporation of America Holdings

            12.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            12.2.11.2. Product Portfolio

            12.2.11.3. SWOT Analysis

            12.2.11.4. Strategic Overview

List of Table

Table 01: EMEA Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 02: EMEA Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 03: EMEA Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 04: EMEA Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 06: Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 07: Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 08: Germany Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 09: Germany Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 10: Germany Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 11: U.K. Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 12: U.K. Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 13: U.K. Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 14: France Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 15: France Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 16: France Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 17: Italy Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 18: Italy Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 19: Italy Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 20: Spain Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 21: Spain Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 22: Spain Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 23: Sweden Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 24: Sweden Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 25: Sweden Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 26: Denmark Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 27: Denmark Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 28: Denmark Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 29: Finland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 30: Finland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 31: Finland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 32: Austria Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 33: Austria Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 34: Austria Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 35: Switzerland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 36: Switzerland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 37: Switzerland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 38: Benelux Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 39: Benelux Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 40: Benelux Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 41: Norway Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 42: Norway Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 43: Norway Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 44: Poland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 45: Poland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 46: Poland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 47: Rest of Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 48: Rest of Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 49: Rest of Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 50: Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 51: Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 52: Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 53: Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 54: GCC Countries Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 55: GCC Countries Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 56: GCC Countries Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 57: GCC Countries Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 58: South Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 59: South Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 60: South Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 61: Rest of Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 62: Rest of Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

List of Figure

Figure 01: EMEA Vaginal Panel Testing Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: EMEA Vaginal Panel Testing Market Value Share, by Application, 2020

Figure 03: EMEA Vaginal Panel Testing Market Value Share, by Type, 2020

Figure 04: EMEA Vaginal Panel Testing Market Value Share, by End-user, 2020

Figure 05: EMEA Vaginal Panel Testing Market Value Share, by Region, 2020

Figure 06: EMEA Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 07: EMEA Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 08: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Direct Molecular DNA Probe, 2017–2031

Figure 09: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Molecular Nucleic Acid Amplification Test (NAAT), 2017–2031

Figure 10: EMEA Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 11: EMEA Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 12: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Bacterial Vaginosis, 2017–2031

Figure 13: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Vulvovaginal Candidiasis, 2017–2031

Figure 14: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Chlamydia, 2017–2031

Figure 15: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Gonorrhoea, 2017–2031

Figure 16: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Trichomoniasis, 2017–2031

Figure 17: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Others, 2017–2031

Figure 18: EMEA Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 19: EMEA Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 19: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Others, 2017–2031

Figure 20: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Hospitals, 2017–2031

Figure 21: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Diagnostic Centers, 2017–2031

Figure 22: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Others, 2017–2031

Figure 23: EMEA Vaginal Panel Testing Market Analysis, 2020 and 2031

Figure 24: EMEA Vaginal Panel Testing Market Attractiveness Analysis, by Region, 2021–2031

Figure 25: Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 26: Europe Vaginal Panel Testing Market Value Share, by Country/Sub-region, 2020–2031

Figure 27: Europe Vaginal Panel Testing Market Attractiveness Analysis by Country/Sub-region, 2021–2031

Figure 28: Europe Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 29: Europe Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 30: Europe Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 31: Europe Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 32: Europe Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 33: Europe Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 34: Germany Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 35: Germany Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 36: Germany Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 37: Germany Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 38: Germany Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 39: Germany Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 40: U.K. Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 41: U.K. Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 42: U.K. Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 43: U.K. Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 44: U.K. Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 45: U.K. Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 46: France Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 47: France Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 48: France Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 49: France Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 50: France Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 51: France Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 52: Italy Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 53: Italy Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 54: Italy Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 55: Italy Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 56: Italy Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 57: Italy Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 58: Spain Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 59: Spain Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 60: Spain Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 61: Spain Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 62: Spain Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 63: Spain Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 64: Sweden Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 65: Sweden Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 66: Sweden Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 67: Sweden Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 68: Sweden Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 69: Sweden Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 70: Denmark Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 71: Denmark Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 72: Denmark Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 73: Denmark Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 74: Denmark Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 75: Breakdown of Net Sales (%), by Business Segment, 2020

Figure 75: Denmark Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 76: Breakdown of Net Sales (%), by Region, 2020

Figure 76: Finland Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 77: Finland Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 78: Finland Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 79: Finland Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 80: Finland Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 81: Finland Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 82: Austria Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 83: Austria Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 84: Austria Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 85: Austria Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 86: Austria Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 87: Austria Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 88: Switzerland Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 89: Switzerland Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 90: Switzerland Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 91: Switzerland Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 92: Switzerland Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 93: Switzerland Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 94: Benelux Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 95: Benelux Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 96: Benelux Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 97: Benelux Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 98: Benelux Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 99: Benelux Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 100: Norway Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 101: Norway Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 102: Norway Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 103: Norway Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 104: Norway Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 105: Norway Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 106: Poland Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 107: Poland Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 108: Poland Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 109: Poland Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 110: Poland Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 111: Rest of Europe Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 112: Rest of Europe Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 113: Rest of Europe Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 114: Rest of Europe Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 115: Rest of Europe Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 116: Rest of Europe Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 117: Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 118: Middle East & Africa Vaginal Panel Testing Market Value Share, by Country/Sub-region, 2020–2031

Figure 119: Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 120: Middle East & Africa Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 121: Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 122: Middle East & Africa Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 123: Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 124: Middle East & Africa Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 125: Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 126: GCC Countries Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 127: GCC Countries Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 128: GCC Countries Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 129: GCC Countries Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 130: GCC Countries Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 131: GCC Countries Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 132: South Africa Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 133: South Africa Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 134: South Africa Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 135: South Africa Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 136: South Africa Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 137: South Africa Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 138: Rest of Middle East & Africa Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

Figure 139: Rest of Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

Figure 140: Rest of Middle East & Africa Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

Figure 141: Rest of Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

Figure 142: Rest of Middle East & Africa Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

Figure 143: Rest of Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

Figure 144: Vaginal Testing Panels Market Share, by Company, 2020

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Vaginal Panel Testing Market